linjc16/ctgov huggingface dataset:
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to collect and report technical success of direct endoscopic ultrasound guided hepatic and portal vein pressure measurement obtained with EchoTip® Insight™ in patients with cirrhosis who are referred for an EGD and/or EUS.

Official Title
-----------------
PORTAL: Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Conditions
-----------------
Liver Cirrhosis, Liver Diseases, Hypertension, Portal

Intervention / Treatment
-----------------
* Device: EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who has been referred for an EGD and/or EUS procedure and direct pressure measurement. General Exclusion Criteria: Patient is pregnant, breast-feeding, or planning to become pregnant during the course of the study. Patient is unwilling or unable to sign and date the informed consent. Patient is unwilling or unable to comply with the follow-up study schedule. Patient for whom endoscopic procedures are contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Portal Pressure Gradient Measurement | Number of participants that the Portal Pressure Gradient measurement was obtainable. | once the measurement is calculated (approximately 1 hour) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fatty Liver, portal pressure measurement, portal pressure gradient
Accuracy of Digital Three-Dimensional Root Position Prediction Via Digitized Models

Study Overview
=================
Brief Summary
-----------------
Measuring the accuracy of a new technique by which root positions can be predicted at the pre-finishing stage of the comprehensive orthoodntic treatment

Detailed Description
-----------------
A CBCT is taken Pre-Treatment Segmentation of teeth is done from the CBCT exported as STL files and kept aside. Routine comprehensive orthodontic treatment is done till pre-finishing stage. Impression for teeth is taken at this timepoint. A cast is poured and laser scanned. Now the investigators have segmented teeth and a cast with new crown positions The investigators will superimpose the teeth on the crowns of the digital cast to obtain the  Predicted Root Position (PRP) To check accuracy of this Prediction a CBCT is taken and compared to the prediction to check its accuracy.

Official Title
-----------------
Accuracy of Digital Three-Dimensional Root Position Prediction Via Digitized Models

Conditions
-----------------
Orthodontic Appliance Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients requiring orthodontic treatment Adult set of permanent dentition Non-extraction cases Exclusion Criteria: Syndromic patients

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of Root Position Prediction as assessed by Color Map Heat Analysis | Using Color Map Heat Analysis in millimetres | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Orthodontics, Digitized Models, Root Position
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.

Official Title
-----------------
A Multicenter, Randomized, Phase 2, Double-blind, Vehicle-controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of Q301 Cream in Adolescents and Adults With Mild to Moderate Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Q301 Cream
* Drug: Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient, for a period of at least three months, has had a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist. Patient has an Investigator's Global Assessment (IGA) score of 2 or 3 corresponding to mild or moderate AD Patient is in good general health and free of any disease state or physical condition that might impair evaluation of AD or which, in the investigator's opinion, exposes the patient to an unacceptable risk by study participation. Exclusion Criteria: Patient has used within four weeks prior to randomization, systemic treatment with: 1) corticosteroids, 2) cyclosporine, 3) other immunosuppressive treatment or any medication known to affect AD (e.g., JAK inhibitors, etc.).

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Vehicle<br> | Drug: Vehicle<br>* Vehicle Control<br>|
| Experimental: 1.0% Q301 Cream<br> | Drug: Q301 Cream<br>* 1.0% or 1.4% Q301 Cream<br>|
| Experimental: 1.4% Q301 Cream<br> | Drug: Q301 Cream<br>* 1.0% or 1.4% Q301 Cream<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and at least a two grade improvement in IGA score |  | Week 8 |
Bariatric Surgery and Skeletal Health

Study Overview
=================
Brief Summary
-----------------
Bone loss may occur after bariatric (weight loss) surgery, but standard methods of measuring bone density in obese patients are potentially inaccurate. This study uses quantitative computed tomography to examine changes in bone mineral density after bariatric surgery. We are also studying mechanisms which may explain bone loss after bariatric surgery.

Official Title
-----------------
Effects of Bariatric Surgery on Skeletal Health

Conditions
-----------------
Morbid Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Either scheduled for Roux-en-Y Gastric Bypass surgery or enrolled in a lifestyle weight management program Exclusion Criteria: Weight ≥ than 450 lbs Postmenopausal women Significant heart, kidney, liver, or malignant disease Current disorders known to affect bone Use of medications known to affect bone for more than 7 days in the past 12 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgical<br>Roux-en-Y gastric bypass surgery | |
| Non-surgical<br>Non-surgical lifestyle weight management | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in bone mineral density by dual-energy x-ray absorptiometry (DXA) and quantitative computed tomography (QCT) |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in serum and/or urine indices of bone formation and bone resorption, such as aminoterminal propeptide of type I collagen [PINP], osteocalcin, C-telopeptide cross-links [CTX]) |  | 1 year | 
| Changes in bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bariatric surgery
SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases

Study Overview
=================
Brief Summary
-----------------
Biopsies are performed in several autoimmune diseases to diagnose or classify them Tolerance and information of the patients have been poorly evlauated our objective is to evaluate tolerance and information of the patients after the biopsies for salivary gland, temporal arteries and neuromuscular.

Detailed Description
-----------------
patinets that benefited of arterial temporal biospy or salivary gland biospy or muscuar biopsy or neuro muscular biospy for his auto -mmune disease will be included and fill standardized questionnaires concerning tolerance, information and side effect at inclusion , day 7 and day 30 after the biopsy data will be analysed to evaluate information, tolerance and risk factor af side effect

Official Title
-----------------
SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases

Conditions
-----------------
Tolerance, Biopsy Site Itching

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: biospy required for the diagnsis or follow up aged of more than 18 non opposition form Exclusion Criteria: unable to consent demencia unable to fill the form and questionnaire patient Under juridical protection refusing to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Salivary gland biospy,<br>100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease. | |
| muscular biopsy,<br>muscular biospy use for the diagnosis of muscular auto-immune disease. | |
| neuro muscular biospy<br>neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease | |
| temporal arteries biospy<br>temporal arteries biospy uses for the diagnosis of giant cell arteritis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tolerance of each type of biopsy | tolerance based on a standardized patient 's questionnaire | tolerance at day 7 after the biospy was performed | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tolerance of each type of biopsy 30 days after | tolerance based on a standardized patient 's questionnaire | tolerance at day 30 and at inclusion after the biospy was performed | 
| evaluation of the qualitiy of patient's information at inclusion | standardized questionnaire at inclusion | questionnaire at inclusion | 
| risk factor of sied effect of each biospy | standardized questionnaire | standardized questionnaire at inclusion, day 7 and 30 |
High Tibial Osteotomy for Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
A prospective, randomised, controlled trial compared two different techniques of high tibial osteotomy with a lateral closing wedge or a medial opening wedge, stabilised by a Puddu plate. The clinical outcome and radiological results were examined at one year.

Detailed Description
-----------------
A prospective, randomised, controlled trial compared two different techniques of high tibial osteotomy with a lateral closing wedge or a medial opening wedge, stabilised by a Puddu plate. The clinical outcome and radiological results were examined at one year. The primary outcome measure was the achievement of an overcorrection of valgus of 4°. Secondary outcome measures were the severity of pain (visual analogue scale), knee function (Hospital for Special Surgery score), and walking distance.

Official Title
-----------------
High Tibial Osteotomy for Osteoarthritis of the Knee: a Randomised Controlled Trial

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Procedure: Opening-wedge HTO
* Procedure: Closing-wedge HTO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Radiological OA, medial joint pain and varus malalignment Exclusion Criteria: Symptomatic OA of the lateral compartment, rheumatoid arthritis, ROM <100, collateral ligament laxity, history of fracture of previous open operation of the lower limb and a flexion contracture > 10 degrees.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Opening-wedge HTO<br>Opening-wedge high tibial osteotomy fixated with a Puddu-plate | Procedure: Opening-wedge HTO<br>* Opening-wedge high tibial osteotomy fixated with a Puddu plate<br>* Other names: open wedge high tibial osteotomy;|
| Active Comparator: Closing-wedge HTO<br>Closing-wedge high tibial osteotomy fixated with 2 staples | Procedure: Closing-wedge HTO<br>* Closing-wedge high tibial osteotomy fixated with two staples<br>* Other names: Closed wedge high tibial osteotomy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The achievement of an overcorrection of valgus of 4°. | The achieved correction will be determined on a whole leg radiograph. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of pain | Severity of pain will be measured with the visual analogue scale | one year | 
| Knee function | Knee function will be measured with the Hospital for Special Surgery score | one year | 
| Walking distance |  | one year |
Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Conditions
-----------------
Asthma, Bronchial, Bronchial Asthma

Intervention / Treatment
-----------------
* Drug: tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of asthma Patients treated with inhaled corticosteroid FEV1 (forced expiratory volume in 1 second)>60% to 80% Exclusion Criteria: Respiratory infection within 2 weeks Asthma exacerbation within 90 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tacrolimus|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tacrolimus, Immunosuppressant, Anti-asthmatic drug, Administration, inhalation
A Behavioral Intervention to Decrease Vomiting and Improve Weight Loss in Post-Operative Laparoscopic Adjustable Gastric Banding (LAGB) Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to reduce problematic vomiting and associated gastrointestinal symptoms in post-operative LAGB patients. We hypothesize that our behavioral intervention will yield greater reductions in vomiting and associated symptoms compared to our control condition.

Conditions
-----------------
Bariatric Surgery Complications

Intervention / Treatment
-----------------
* Behavioral: behavioral intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 70 years. Received LAGB surgery with either a standard Lap-Band or a standard Realize Band. Report vomiting at least 3x/week. Agree to allow researchers to communicate with their surgeon regarding their care. Fulfilled all hospital surgery criteria. Exclusion Criteria: Report a condition that in the judgment of the Principal Investigator would render them potentially unlikely to follow the protocol (e.g., major illness, plans to move out of the area, substance abuse or other significant psychiatric problems, organic brain disease). Report planning to become pregnant during the time frame of the investigation. Report a history of upper gastrointestinal dismotility.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: behavioral intervention<br> | Behavioral: behavioral intervention<br>* This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.<br>|
| No Intervention: no treatment control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in frequency of self-reported vomiting (number of vomiting episodes each week) measured via structured interview |  | baseline to week 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in gastrointestinal symptom severity - questionnaire measures severity of various GI symptoms over the previous week and items are summed yielding an overall GI severity index |  | baseline to week 6 |
Glycocalyx Damage in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
The hypothesis to be tested: GCX damage and its dynamics correlate to various patient related factors and to using organ-supporting measures. There is a correlation between length of organ support and GCX damage. The aim of the study: Evaluation of the relationship between GCX damage and duration of various organ supporting measures. Type of the study: Observational. Subjects: Adult patients admitted to ICU and requiring organ supporting therapy. Sample size: We plan enrollment of 75 patients on invasive ventilatory support in the duration of least 5 days, 50 patients on renal supporting therapy lasting at least 5 days and 20 patients with target temperature management for neuroprotection. Intervention: none Data to be recorded and analysed: Demographics, type of patients (trauma, post surgical, medical, after cardiac arrest), severity score - Apache II, SOFA, fluid balance, presence of delirium, clinical outcome, sublingual microcirculation by SDF imaging at time points: before or at the start of organ support, after 24 hours (day 1), day 3, 5, 7 and/or at discharge or before death, microcirculatory data, and Perfused Boundary Region.

Official Title
-----------------
Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection

Conditions
-----------------
Critical Illness

Intervention / Treatment
-----------------
* Device: PBR assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients admitted to ICU artifitial ventilation renal replacement therapy targeted temperatura management Exclusion Criteria: pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients on artificial ventilation<br> | Device: PBR assessment<br>* Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.<br>|
| Patients on renal replacement therapy<br> | Device: PBR assessment<br>* Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.<br>|
| Patients with targeted temperature management<br> | Device: PBR assessment<br>* Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfused Boundary Region (PBR) in One Week | PBR is an indirect measure of assessment of the endothelial glycocalyx thickness in sublingual microcirculation. | One week on ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycocalyx